KT 294
Alternative Names: KT-294Latest Information Update: 14 Mar 2024
At a glance
- Originator Kymera Therapeutics
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Skin disorder therapies; Small molecules
- Mechanism of Action TYK2 kinase degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Inflammatory bowel diseases; Psoriasis; Psoriatic arthritis; Systemic lupus erythematosus
Most Recent Events
- 08 Mar 2024 Updated pharmacodynamics data from preclinical studies released by Kymera Therapeutics
- 10 Jan 2024 KT 294 is available for licensing as of 10 Jan 2024. https://www.kymeratx.com/science-innovation/pipeline/
- 10 Jan 2024 Preclinical trials in Inflammatory bowel diseases in USA (PO) before January 2024